IAS 2023 | WHO Guidelines Update: The Risk of HIV Sexual Transmission with Low Viral Load is Nearly Zero  

IAS 2023 | WHO Guidelines Update: The Risk of HIV Sexual Transmission with Low Viral Load is Nearly Zero  

The 12th International AIDS Society Conference on HIV Science (IAS 2023) began on July 23, 2023, in Brisbane, Australia. At the conference, experts from the World Health Organization (WHO) introduced important updates to the HIV guidelines, emphasizing the importance of "HIV viral suppression for improved individual health and reduced transmission." On the eve of the conference, The Lancet published a systematic review showing that the risk of HIV transmission with low-level viral load is almost zero.
IAS 2023 | Joining Hands to Eliminate AIDS Epidemic by 2030

IAS 2023 | Joining Hands to Eliminate AIDS Epidemic by 2030

On July 23, 2023, the 12th International AIDS Society (IAS) HIV Science Conference, referred to as IAS 2023, officially began in Brisbane, Australia. As one of the largest open academic conferences in the global HIV and AIDS field, the event attracted participation from experts, medical professionals, community groups, and medical enterprises worldwide. The conference emphasized the importance of science as the foundation of policy and practice, highlighting the close integration of science, policy, and activism to promote significant advancements in the HIV and AIDS sector. The theme of the conference is "End Inequalities. End AIDS. End Pandemics.", reflecting IAS's ultimate vision. The goal is to rally health experts globally towards the shared ambition of eradicating AIDS by 2030.
IAS 2023 | Thymosin α1 Therapy for HIV Immunological Non-responders: A Single-arm Clinical Study

IAS 2023 | Thymosin α1 Therapy for HIV Immunological Non-responders: A Single-arm Clinical Study

As HIV treatment enters the post-ART era, drug side effects and complications have become significant factors affecting the quality of life for patients. Approximately 20% of patients, after 1-2 years of treatment, have viral loads below the detectable limit, but their CD4 cell count remains below normal levels, leading to poorer clinical outcomes. From 2021 to 2022, the Shanghai Public Health Clinical Center conducted a clinical study on the use of thymosin α1 for the treatment of HIV immunological non-responders. The study results were presented as an e-poster at the IAS 2023 conference (Abstract No. 4511). A total of 20 participants were enrolled in the study, undergoing treatment and follow-up for a duration of six months (Registration No. NCT04963712).